Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care    FME   DE0005785802

FRESENIUS MEDICAL CARE (FME)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
88.74(c) 89.08(c) 89.42(c) 89.78(c) 91.06(c) Last
587 469 463 474 567 064 517 299 706 970 Volume
-0.69% +0.38% +0.38% +0.40% +1.43% Change
More quotes
Financials (€)
Sales 2017 17 884 M
EBIT 2017 2 549 M
Net income 2017 1 261 M
Debt 2017 7 198 M
Yield 2017 1,09%
Sales 2018 18 852 M
EBIT 2018 2 715 M
Net income 2018 1 348 M
Debt 2018 7 508 M
Yield 2018 1,16%
P/E ratio 2017 22,38
P/E ratio 2018 21,06
EV / Sales2017 1,97x
EV / Sales2018 1,89x
Capitalization 28 057 M
More Financials
Company
Fresenius Medical Care AG & Co. KGaA provides products and services for patients with chronic kidney failure.Its products include dialysis machines, dialyzers, and related disposables.It also offers renal information technology solutions and provides services such as renal replacement therapy and... 
More about the company
Surperformance© ratings of Fresenius Medical Care
Trading Rating : Investor Rating :
More Ratings
Latest news on FRESENIUS MEDICAL CARE
2017 FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 26a of the W..
2017 FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
2017 FRESENIUS : FMC Expect Positive Impact From U.S. Tax Reform
2017 AD HOC ANNOUNCEMENT ACCORDING TO ART : Fresenius Medical Care expects material p..
2017 FRESENIUS MEDICAL CARE : Expects Material Positive Effects From US Tax Reform
2017 FRESENIUS MEDICAL CARE : expects material positive effects from US tax reform
2017 U.S. tax cuts mix pleasure and pain for Europe's dollar earners
2017 FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
2017 FRESENIUS MEDICAL CARE : closes divestment of Shiel Medical Laboratory to Quest ..
2017 FRESENIUS MEDICAL CARE : closes divestment of Shiel Medical Laboratory to Quest ..
More news
Sector news : Healthcare Facilities & Services - NEC
01/07 Fresenius CFO backs acquisition course - Boersen-Zeitung
2017 FRESENIUS : FMC Expect Positive Impact From U.S. Tax Reform
2017 FRESENIUS : Expects Meaningful Positive Effects From US Tax Reform
2017 EXCLUSIVE - LONDON-LISTED NMC IN TAL : sources
2017 FRESENIUS : to Open New Hospital in Spain
More sector news : Healthcare Facilities & Services - NEC
4-Traders Strategies on FRESENIUS MEDICAL CARE 
FRESENIUS MEDICAL CARE - 2017
The technical configuration is positive
BUY
FRESENIUS MEDICAL CARE - 2017
Comeback of a rising trend ?
BUY
More Strategies
Latest Tweets
01/15Hikma names ex-Fresenius scientist as global R&D chief  
01/12Fresenius Kabi Introduces Bortezomib for Injection: LAKE ZURICH, Ill.--(BUSIN.. 
01/12Fresenius Kabi Introduces Bortezomib for Injection  
01/11Somewhat Favorable News Coverage Somewhat Unlikely to Impact Fresenius Medica.. 
01/10Reviewing Fresenius Medical Care AG & Co. $FMS and HealthStream $HSTM  
More tweets
Qtime:98
News from SeekingAlpha
01/20 FRESENIUS : Proven Value Creation Amidst M&A Doubts
01/18 Hospitals still grappling with IV fluid shortage
01/15 ROAD TO FINANCIAL INDEPENDENCE : My December 88-Stock Portfolio Review
01/02 Fresenius SE - Is Last Year's Underperformer A Good Investment For 2018?
2017 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
Chart FRESENIUS MEDICAL CARE
Duration : Period :
Fresenius Medical Care Technical Analysis Chart | FME | DE0005785802 | 4-Traders
Technical analysis trends FRESENIUS MEDICAL CARE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 91,3 €
Spread / Average Target 0,25%
EPS Revisions
Managers
NameTitle
Rice Powell Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Michael Brosnan Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Dieter Schenk Vice Chairman-Supervisory Board
Sector and Competitors